<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1110">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092427</url>
  </required_header>
  <id_info>
    <org_study_id>P150934</org_study_id>
    <nct_id>NCT03092427</nct_id>
  </id_info>
  <brief_title>Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)</brief_title>
  <acronym>PERMAJI</acronym>
  <official_title>Evaluation of the Effectiveness of a Probiotic Treatment on Clinical Activity, Relapse Rates and Modification of the Intestinal Microbiota in Patients With Juvenile Idiopathic Arthritis (JIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy of probiotic VSL#3 as an add on standard care on the
      activity of the disease in patients with Juvenile Idiopathic Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Juvenile Idiopathic Arthritis (JIA) is the most frequent rheumatic disorder in children.
      Numerous studies suggest that alteration of the intestinal barrier may induce abnormal
      immune responses implicated in development or persistence of arthritis. This paves the way
      to new therapeutic options aiming to reestablish intestinal homeostasis to treat arthritis
      or to prevent disease flares. This study investigates the efficacy of probiotic VSL#3 as an
      add on standard care on the activity of the disease in patients with Juvenile Idiopathic
      Arthritis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the clinical activity</measure>
    <time_frame>3 months</time_frame>
    <description>American College of Rheumatology Pédiatrique score (ACR Pedi )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the intestinal microbiota.</measure>
    <time_frame>3 months</time_frame>
    <description>Stool samples for intestinal microbiota analyses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Probiotic VSL#3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>Dietary Supplement</description>
    <arm_group_label>Probiotic VSL#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥1year and &lt;7years

          -  Patients with oligoarthritis and polyarthritis with rheumafactor negative and
             antinuclear antibodies (ANA) positive JIA with onset before the age of 6 years

        Exclusion Criteria:

          -  Change of JIA forme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ulrich Meinzer, MD/PhD</last_name>
    <phone>33 1 40 03 20 48</phone>
    <email>ulrich.meinzer@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albert Faye, MD/PhD</last_name>
    <phone>33 1 40 03 53 61</phone>
    <email>albert.faye@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>March 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
